Cargando…

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy

We improve the potency of antibody-drug conjugates (ADCs) containing the HER2-specific antibody pertuzumab by reducing their affinity for HER2 by >250-fold at acidic endosomal pH relative to near neutral pH. These engineered pertuzumab variants show increased lysosomal delivery and cytotoxicity t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Jeffrey C., Sun, Wei, Khare, Priyanka, Karimi, Mostafa, Wang, Xiaoli, Shen, Yang, Ober, Raimund J., Ward, E. Sally
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668989/ https://www.ncbi.nlm.nih.gov/pubmed/30936563 http://dx.doi.org/10.1038/s41587-019-0073-7

Ejemplares similares

Engineered clearing agents for the selective depletion of antigen-specific antibodies
por: Devanaboyina, Siva Charan, et al.
Publicado: (2017)

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
por: Kang, Jeffrey C, et al.
Publicado: (2014)

Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET
por: Khare, Priyanka, et al.
Publicado: (2021)

The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells
por: Ram, Sripad, et al.
Publicado: (2014)

Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease
por: Sun, Wei, et al.
Publicado: (2021)

Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption
por: Swiercz, Rafal, et al.
Publicado: (2016)

Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates
por: Balamkundu, Seetharamsing, et al.
Publicado: (2023)

Phagocytosis of antibody‐opsonized tumor cells leads to the formation of a discrete vacuolar compartment in macrophages
por: Velmurugan, Ramraj, et al.
Publicado: (2018)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

Commentary: “There’s been a Flaw in Our Thinking”
por: Ward, E. Sally, et al.
Publicado: (2015)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates (AOCs)
por: Malecova, Barbora, et al.
Publicado: (2023)

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index
por: Hui, Xiwu, et al.
Publicado: (2022)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors
por: Wu, Shou-Cheng, et al.
Publicado: (2016)

BRCAA1 antibody- and Her2 antibody-conjugated amphiphilic polymer engineered CdSe/ZnS quantum dots for targeted imaging of gastric cancer
por: Li, Chao, et al.
Publicado: (2014)

Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis
por: Challa, Dilip K., et al.
Publicado: (2019)

Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells
por: Otis, James B., et al.
Publicado: (2016)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Ultrahigh accuracy imaging modality for super-localization microscopy
por: Chao, Jerry, et al.
Publicado: (2013)

Fluorescent Microspheres as Point Sources: A Localization Study
por: Chao, Jerry, et al.
Publicado: (2015)

Molecular Engineering of Peptide–Drug Conjugates for Therapeutics
por: Fang, Yu, et al.
Publicado: (2022)

Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
por: Dou, Xiao-qian, et al.
Publicado: (2018)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
por: Chiang, Zu-Chian, et al.
Publicado: (2020)

Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates
por: Feuillâtre, Ofelia, et al.
Publicado: (2020)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
por: Leyton, Jeffrey V.
Publicado: (2020)

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
por: Sheyi, Rotimi, et al.
Publicado: (2022)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Therapeutic index improvement of antibody-drug conjugates
por: Gerber, Hans-Peter, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_omso0uja1sv7n9tkb4bb70fjtk